Venous thromboembolism has always been the main serious harm of combined oral contraceptives, and the estrogen component drives much of it. A clinical review argues that the natural-estrogen formulations now available carry an improved safety profile while keeping high contraceptive efficacy.
On that basis the authors suggest natural-estrogen combined pills should likely be the first choice for new-start patients, rather than the older ethinylestradiol formulations. The reasoning rests on the specific estrogen and progestin in each product, so the choice should still be matched to the individual woman's venous thromboembolism and cardiovascular risk.
This is expert opinion rather than a guideline change, so weigh it against current local guidance and product availability. Whatever the formulation, counsel every new starter that venous thromboembolism risk is highest in the first months of use.
- Natural-estrogen combined oral contraceptives have an improved safety profile at similar efficacy.
- The review suggests them as first line for new-start patients.
- Match the specific estrogen and progestin to the woman's venous thromboembolism and cardiovascular risk.
- Counsel every new starter that venous thromboembolism risk is highest in the first months of use.
Why it matters
Venous thromboembolism has always been the main serious harm of combined pills, and newer estrogens may keep the benefits with less of that risk.
Don't overread it
This is a clinical review, not a guideline change — it recommends a direction, it does not yet reflect updated standards.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for obstetrics & gynaecology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free